UA73784C2 - Tablet, obtainable by direct compression, comprising 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid as active ingredient - Google Patents

Tablet, obtainable by direct compression, comprising 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid as active ingredient Download PDF

Info

Publication number: UA73784C2
Authority: UA; Ukraine
Prior art keywords: tablet; diluent; mannitol; lactose; active ingredient
Prior art date: 2000-07-11

Application number

UA2003021190A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2001-06-29

Publication date

2005-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5471285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA73784(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-29 Application filed filed Critical

2005-09-15 Publication of UA73784C2 publication Critical patent/UA73784C2/uk

Links

239000004480 active ingredient Substances 0.000 title claims abstract description 25
238000007907 direct compression Methods 0.000 title abstract description 5
239000003085 diluting agent Substances 0.000 claims abstract description 52
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 43
239000008101 lactose Substances 0.000 claims abstract description 42
239000002253 acid Substances 0.000 claims abstract description 19
239000002706 dry binder Substances 0.000 claims abstract description 12
239000000314 lubricant Substances 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 7
239000003795 chemical substances by application Substances 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 80
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 44
239000008108 microcrystalline cellulose Substances 0.000 claims description 44
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 44
229940016286 microcrystalline cellulose Drugs 0.000 claims description 43
229930195725 Mannitol Natural products 0.000 claims description 39
239000000594 mannitol Substances 0.000 claims description 39
235000010355 mannitol Nutrition 0.000 claims description 39
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 37
238000003825 pressing Methods 0.000 claims description 20
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 11
239000001913 cellulose Substances 0.000 claims description 11
235000019700 dicalcium phosphate Nutrition 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
239000007884 disintegrant Substances 0.000 claims description 6
239000011230 binding agent Substances 0.000 claims description 5
229920000881 Modified starch Polymers 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
235000019426 modified starch Nutrition 0.000 claims description 4
235000021317 phosphate Nutrition 0.000 claims description 4
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
235000019814 powdered cellulose Nutrition 0.000 claims description 3
229920003124 powdered cellulose Polymers 0.000 claims description 3
239000003513 alkali Substances 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 45
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 42
229960001375 lactose Drugs 0.000 description 40
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 26
235000019359 magnesium stearate Nutrition 0.000 description 23
238000000034 method Methods 0.000 description 21
239000000126 substance Substances 0.000 description 19
229920002261 Corn starch Polymers 0.000 description 16
239000008120 corn starch Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
229960004343 alendronic acid Drugs 0.000 description 15
230000008569 process Effects 0.000 description 15
239000000546 pharmaceutical excipient Substances 0.000 description 13
239000003814 drug Substances 0.000 description 11
229940062527 alendronate Drugs 0.000 description 10
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 10
229920002472 Starch Polymers 0.000 description 9
235000019698 starch Nutrition 0.000 description 9
150000007513 acids Chemical class 0.000 description 8
235000010980 cellulose Nutrition 0.000 description 8
229920002678 cellulose Polymers 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
238000009472 formulation Methods 0.000 description 7
239000008107 starch Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
238000007906 compression Methods 0.000 description 6
230000006835 compression Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000000265 homogenisation Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
238000005469 granulation Methods 0.000 description 5
230000003179 granulation Effects 0.000 description 5
238000013112 stability test Methods 0.000 description 5
238000005550 wet granulation Methods 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
229960004977 anhydrous lactose Drugs 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
230000009471 action Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000005457 optimization Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229950008138 carmellose Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940057948 magnesium stearate Drugs 0.000 description 2
235000019691 monocalcium phosphate Nutrition 0.000 description 2
230000030991 negative regulation of bone resorption Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
229940122361 Bisphosphonate Drugs 0.000 description 1
206010007027 Calculus urinary Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
-1 sodium carmellose salt Chemical class 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000008281 urolithiasis Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2003021190A 2000-07-11 2001-06-29 Tablet, obtainable by direct compression, comprising 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid as active ingredient UA73784C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CZ20002567A CZ20002567A3 (cs)	2000-07-11	2000-07-11	Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
PCT/CZ2001/000037 WO2002003963A1 (fr)	2000-07-11	2001-06-29	Comprime obtenu par compression directe et renfermant de l'acide 4-amino-1-hydroxybutylidene-1,1-biphosphonique en tant qu'ingredient actif

Publications (1)

Publication Number	Publication Date
UA73784C2 true UA73784C2 (en)	2005-09-15

Family

ID=5471285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003021190A UA73784C2 (en)	2000-07-11	2001-06-29	Tablet, obtainable by direct compression, comprising 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid as active ingredient

Country Status (17)

Country	Link
US (1)	US7198802B2 (fr)
EP (1)	EP1299088B1 (fr)
AT (1)	ATE331502T1 (fr)
AU (1)	AU2001270454A1 (fr)
BG (1)	BG107520A (fr)
CA (1)	CA2415630A1 (fr)
CZ (1)	CZ20002567A3 (fr)
DE (1)	DE60121166D1 (fr)
EE (1)	EE200300017A (fr)
HR (1)	HRP20020735A2 (fr)
HU (1)	HUP0301072A3 (fr)
PL (1)	PL360872A1 (fr)
RU (1)	RU2279273C2 (fr)
SK (1)	SK283249B6 (fr)
UA (1)	UA73784C2 (fr)
WO (1)	WO2002003963A1 (fr)
YU (1)	YU77702A (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6827718B2 (en)	2001-08-14	2004-12-07	Scimed Life Systems, Inc.	Method of and apparatus for positioning and maintaining the position of endoscopic instruments
AU2003230805A1 (en) *	2002-04-05	2003-10-27	Penwest Pharmaceuticals Co.	Sustained release metoprolol formulations
GR1004331B (el) *	2002-10-07	2003-09-05	Verisfield (Uk) Ltd	Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
WO2006018033A1 (fr) *	2004-08-20	2006-02-23	Mepha Ag	Formulations de bisphosphonates
WO2006046100A1 (fr) *	2004-10-25	2006-05-04	Ranbaxy Laboratories Limited	Composition pharmaceutique a base d'acide alendronique
WO2006054165A1 (fr) *	2004-11-19	2006-05-26	Ranbaxy Laboratories Limited	Compositions pharmaceutiques de l'acide alendronique et leur procede de preparation
US9050391B2 (en)	2005-10-27	2015-06-09	Nexilis Ag	Implant and production method for said implant
FR2918567B1 (fr) *	2007-07-11	2012-08-03	Pf Medicament	Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
US20110229566A1 (en) *	2008-08-22	2011-09-22	Yatendra Kumar Gupta	Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
WO2010133629A1 (fr) *	2009-05-19	2010-11-25	Grindeks, A Joint Stock Company	Composition pharmaceutique stable de phosphate de fludarabine
EP2512455B8 (fr)	2009-12-18	2014-07-23	FrieslandCampina Nederland Holding B.V.	Composition d'excipient de comprimé co-traité, sa préparation et son utilisation
WO2023025672A1 (fr)	2021-08-25	2023-03-02	Basf Se	Composition auxiliaire de compression directe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5358941A (en) *	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
CZ287984B6 (cs) *	1993-05-15	2001-03-14	Roche Diagnostics Gmbh	Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby
US5853759A (en) *	1996-05-17	1998-12-29	Merck & Co.. Inc.	Effervescent alendronate formulation
EP1035869A1 (fr) *	1997-03-26	2000-09-20	Sepracor, Inc.	Formulations chimiquement et thermiquement stables de norastemizole
PL358593A1 (en) *	2000-04-07	2004-08-09	Pfizer Products Inc.	Estrogen agonist/antagonist metabolites

2000
- 2000-07-11 CZ CZ20002567A patent/CZ20002567A3/cs not_active IP Right Cessation
2001
- 2001-04-12 SK SK511-2001A patent/SK283249B6/sk not_active IP Right Cessation
- 2001-06-29 RU RU2003102448/15A patent/RU2279273C2/ru not_active IP Right Cessation
- 2001-06-29 AU AU2001270454A patent/AU2001270454A1/en not_active Abandoned
- 2001-06-29 HU HU0301072A patent/HUP0301072A3/hu unknown
- 2001-06-29 UA UA2003021190A patent/UA73784C2/uk unknown
- 2001-06-29 DE DE60121166T patent/DE60121166D1/de not_active Expired - Fee Related
- 2001-06-29 YU YU77702A patent/YU77702A/sh unknown
- 2001-06-29 US US10/257,958 patent/US7198802B2/en not_active Expired - Fee Related
- 2001-06-29 EP EP01949210A patent/EP1299088B1/fr not_active Expired - Lifetime
- 2001-06-29 WO PCT/CZ2001/000037 patent/WO2002003963A1/fr not_active Ceased
- 2001-06-29 CA CA002415630A patent/CA2415630A1/fr not_active Abandoned
- 2001-06-29 EE EEP200300017A patent/EE200300017A/xx unknown
- 2001-06-29 PL PL36087201A patent/PL360872A1/xx not_active IP Right Cessation
- 2001-06-29 HR HRP20020735 patent/HRP20020735A2/xx not_active Application Discontinuation
- 2001-06-29 AT AT01949210T patent/ATE331502T1/de not_active IP Right Cessation
2003
- 2003-02-04 BG BG107520A patent/BG107520A/bg unknown

Also Published As

Publication number	Publication date
RU2279273C2 (ru)	2006-07-10
DE60121166D1 (de)	2006-08-10
BG107520A (bg)	2003-06-30
SK5112001A3 (en)	2002-02-05
CZ289261B6 (cs)	2001-12-12
AU2001270454A1 (en)	2002-01-21
EP1299088B1 (fr)	2006-06-28
EE200300017A (et)	2004-10-15
CA2415630A1 (fr)	2002-01-17
EP1299088A1 (fr)	2003-04-09
HUP0301072A2 (hu)	2003-08-28
CZ20002567A3 (cs)	2001-12-12
SK283249B6 (sk)	2003-04-01
YU77702A (sh)	2006-05-25
HRP20020735A2 (en)	2004-12-31
PL360872A1 (en)	2004-09-20
HUP0301072A3 (en)	2005-07-28
WO2002003963A1 (fr)	2002-01-17
US20030161878A1 (en)	2003-08-28
ATE331502T1 (de)	2006-07-15
US7198802B2 (en)	2007-04-03

Publication	Publication Date	Title
US3873694A (en)	1975-03-25	Direct compression tabletting composition and pharmaceutical tablets produced therefrom
ES2899417T3 (es)	2022-03-11	Formulación y proceso de compresión directa
UA73078C2 (uk)	2005-06-15	Фармацевтичний препарат у вигляді таблеток на основі солі дихлорметилендифосфорної кислоти та силікатованої мікрокристалічної целюлози та спосіб його одержання
US5348745A (en)	1994-09-20	Aqueous granulation solution and a method of tablet granulation
JPH0660102B2 (ja)	1994-08-10	直接圧縮シクロホスファミド錠剤
US11058671B2 (en)	2021-07-13	Formulations and methods of manufacturing formulations for use in colonic evacuation
US10398653B2 (en)	2019-09-03	Solid preparations containing tofogliflozin and process of producing the same
RU2279273C2 (ru)	2006-07-10	Таблетка, получаемая непосредственным прессованием, содержащая 4-амино-1-гидроксибутилиден-1,1-бисфосфоновую кислоту в качестве активного ингредиента
EP0396972B2 (fr)	1998-06-24	Solution aqueuse de granulation et procédé pour la granulation de comprimés
SK8942000A3 (en)	2001-04-09	Orally administrable solid ribavirin dosage forms and process for making them
JP2004521890A (ja)	2004-07-22	非吸湿性バルプロ酸ナトリウム組成物の製造方法
WO2012078528A2 (fr)	2012-06-14	Formulations effervescentes stables à base de bisphosphonate présentant des caractéristiques de solubilisation rapide
KR102838283B1 (ko)	2025-07-25	시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
EP3920892B1 (fr)	2023-11-15	Forme posologique solide comprenant du gluconate de zinc et de l'inosine pranobex, et procédé de préparation et ses applications
RU2266106C1 (ru)	2005-12-20	Способ получения антимикробного средства
UA68321A (en)	2004-07-15	Tableted pharmaceutical composition containing thyroid hormones and method for its production